Plasma Fractionation Market in terms of revenue was estimated to be worth $26.5 billion in 2022 and is poised to reach $36.3 billion by 2027, growing at a CAGR of 6.5% from 2022 to 2027. The market size is updated for the base year of 2021 and forecasted from 2022 to 2027 by studying the impact of the overall plasma fractionation industry. The new version of the report includes ranges and scenarios, value chain analysis, ecosystem analysis, technology analysis, patent analysis, trends and disruptions impacting customers, Porter’s five forces analysis, and a regulatory landscape. In the earlier version of the report, 20 companies were profiled. In the updated version, a total of 25 companies have been profiled. Market growth is driven mainly by factors such as the growing use of immunoglobulins in various therapeutic areas, the rapidly growing geriatric population, and the rising prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD). However, high costs, limited reimbursements, and the market disruption caused by recombinant alternatives are expected to restrain the growth of this market to a certain extent during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93798284
Browse in-depth TOC on “Plasma Fractionation Market”
380– Tables
46 – Figures
360 – Pages
Key Market Players
Key players in the global plasma fractionation market include CSL (Australia), Grifols, S.A. (Spain), Shire (US), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), Biotest AG (Germany), Sanquin (Netherlands), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Bio Products Ltd. (UK), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), Shanghai Raas Blood Products Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India), SK Plasma (Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), KabaFusion (US), Centurion Pharma (Istanbul), ADMA Biologics, Inc. (US), PlasmaGen BioSciences Pvt. Ltd. (India), Virchow Biotech Private Limited (India), Fusion Healthcare (India), and Hemarus Therapeutics Limited (India).
CSL
In 2021, CSL dominated the plasma fractionation market with a share of 30–35%. It also established itself as a global leader in this market, by focusing on strengthening its presence in the emerging markets. In 2017, CSL invested USD 174 million for capacity expansion to increase its production capacity of albumin at its Broadmeadows facility (Melbourne, Australia) and In 2019, the company announced an investment of USD 203 million at Marburg, Germany, to cater to the increased demand for plasma fractionation products. Such investment in opening new centers and existing presence in 35 countries with over 230 plasma collection centers, in North America, Europe, Australia, and Asia Pacific ensure that their products are available globally.
Continuous investments in R&D have also enabled the company to emerge as a leading provider of plasma fractionation products. In the last five years, the company invested around USD 3.3 billion in developing and delivering innovative biotherapies; it has more than 1,700 employees dedicated to R&D activities.
However, the company’s involvement in legal proceedings and the decline in liquidity ratio could hamper its growth to a certain extent. Stringent government regulations and unfavorable currency exchange rates may also affect the company’s growth in the coming years.
GRIFOLS
Grifols accounted for a share of 15–20% of the plasma fractionation market in 2021. Grifols is a global healthcare company specializing in developing, manufacturing, and distributing plasma-derived products. The company focuses on research and product innovation to maintain its leading position in the market. Grifols invests heavily in R&D, as well as partners with research institutes to develop advanced plasma-derived products to fight rare diseases. The company also constantly focuses on expanding its plasma collection centers and increasing its capacity. It has more than 190 centers in the US and 35 in Europe.
SHIRE
Shire accounted for a share of 11–16% of the plasma fractionation market in 2021. In 2019, Shire was acquired by Takeda. Since Takeda is an internationally recognized brand, the acquisition will help Shire gain a competitive edge in the market. The company’s leading position in the market can also be attributed to its expertise in medical devices, pharmaceuticals, and biotechnology. BioLife, a part of Takeda, is a global plasma collection network that collects high-quality plasma.
Shire also has more than 80 plasma collection facilities in 24 states of the US and at 7 locations in Austria, which helps increase its productivity without making it necessary for the company to spend on outsourcing plasma. The company also maintains relationships with other plasma suppliers to meet the market demand for its plasma-based therapies.
OCTAPHARMA AG
Octapharma AG accounted for 8–12% of the plasma fractionation market in 2021. Octapharma invests in research to advance its existing products as well as investigate new therapeutic uses of human protein products derived from human blood plasma and human cell lines. The company focuses on organic and inorganic growth strategies such as collaborations, product launches, and expansions.
The company also focuses on adopting various promotional strategies to increase brand awareness in the plasma fractionation market. Since 2018, the company has received seven approvals from various regulatory bodies.
KEDRION S.P.A
Kedrion accounted for 2–5% of the plasma fractionation market in 2021. The company has a robust presence in about 100 countries across Asia, Europe, North America, and South America, and 24 plasma collection centers worldwide. Kedrion strategically focuses on collaborations and agreements as its key growth strategy. The company also collaborates with various hemophilia institutes to provide sustainable access to hemophilia treatment by donating plasma-derived products to various developing as well as European countries that do not meet the minimum standards of hemophilia care.
Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=93798284
North America was the largest regional market for plasma fractionation market in 2021
The global plasma fractionation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the growing number of hemophilic patients in the region and the increasing use of immunoglobulins for PID, chronic inflammatory demyelinating polyneuropathy (CIDP), idiopathic thrombocytopenic purpura, pediatric HIV, allogenic bone marrow transplantation, and B-cell chronic lymphocytic leukemia. However, the market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period. This can be attributed to the growth in the overall healthcare industry, increasing number of hemophilic patients, increasing number of organ transplantations, increasing focus on diagnosis and prophylactic treatment, increasing awareness about technologically advanced products, and improving the standard of living in several APAC countries.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=93798284
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/plasma-fractionation.asp
Related Reports:
